Novo Invests $2bn In Diabetes Franchise Growth
This article was originally published in Scrip
Danish diabetes drug maker Novo Nordisk launched a Phase IIIa clinical trial program for the oral version of its glucagon-like peptide-1 (GLP-1) analog semaglutide on 26 August and simultaneously revealed plans to invest $2bn in manufacturing to support the potential blockbuster diabetes drug.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.